1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Cell Works Inc. is a company with 1 orphan drug designation across 3 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| malignant carotid body paraganglioma | tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate | Des.TrialAppr. |
| treatment-refractory schizophrenia | tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio